ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 7.69 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $226.000 thousand which beat the analyst consensus estimate of $143.667 thousand by 57.31 percent. This is a 1.74 percent decrease over sales of $230.000 thousand the same period last year.